Gastrointestinal kreft, kliniske og molekylarbiologiske studier
- Prosjektnummer
- 911728
- Ansvarlig person
- Olav Dahl
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Cancer
- Forskningsaktivitet
- 6. Treatment Evaluation
Brukerne har avgitt samtykke til deltagelse i studien. Denne baseres på vevsprøver fra operasjonspreparater.
Linear energy transfer distributions in the brainstem depending on tumour location in intensity-modulated proton therapy of paediatric cancer.
Acta Oncol 2017 Jun;56(6):763-768. Epub 2017 apr 19
PMID: 28423966
Risk of carotid blowout after reirradiation with particle therapy.
Adv Radiat Oncol 2017 Jul-Sep;2(3):465-474. Epub 2017 jul 6
PMID: 29114615
Multimodal therapy is feasible in elderly anal cancer patients.
Acta Oncol 2017 Jan;56(1):81-87. Epub 2016 nov 3
PMID: 27808666
Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer.
Oncotarget 2017 Oct 20;8(50):87837-87847. Epub 2017 sep 23
PMID: 29152124
CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.
Tumour Biol 2016 Jun;37(6):7441-52. Epub 2015 des 17
PMID: 26678887
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).
Ann Oncol 2016 Jul;27(7):1299-304. Epub 2016 apr 6
PMID: 27052649
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.
Cancer Med 2016 Aug;5(8):1840-9. Epub 2016 jun 8
PMID: 27273130
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Acta Oncol 2016 Dec;55(12):1425-1433. Epub 2016 jul 20
PMID: 27435662
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome.
JCI Insight 2016 Dec 22;1(21):e89376. Epub 2016 des 22
PMID: 28018972
[Treatment for stage I-testicular cancer should be assessed individually].
Tidsskr Nor Laegeforen 2015 Aug 25;135(15):1340-1. Epub 2015 aug 25
PMID: 26315230
Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols.
Acta Oncol 2015 Apr;54(4):493-9. Epub 2014 sep 5
PMID: 25192551
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
PLoS One 2015;10(7):e0129898. Epub 2015 jul 1
PMID: 26132314
Twenty-five years with adjuvant chemotherapy for colon cancer--a continuous evolving concept.
Acta Oncol 2015 Jan;54(1):1-4. Epub 2014 sep 29
PMID: 25263079
Validity of Norwegian Rectal Cancer Registry data at a major university hospital 1997-2005.
Acta Oncol 2015 Nov;54(10):1723-8. Epub 2015 apr 23
PMID: 25904461
Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010.
Acta Oncol 2015 Nov;54(10):1714-22. Epub 2015 apr 30
PMID: 25924970
Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer.
Acta Oncol 2015 Apr;54(4):470-9. Epub 2014 sep 17
PMID: 25227897
Brachytherapy for malignant uveal melanoma.
Tidsskr Nor Laegeforen 2014 Mar 11;134(5):529. Epub 2014 mar 11
PMID: 24621911
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.
Ann Oncol 2014 Nov;25(11):2167-72. Epub 2014 aug 11
PMID: 25114021
The total number of lymph nodes in resected colon cancer specimens is affected by several factors but the lymph node ratio is independent of these.
APMIS 2014 Jun;122(6):490-8. Epub 2013 okt 26
PMID: 24164093
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.
Radiother Oncol 2014 Dec;113(3):352-8.
PMID: 25499203
Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors.
Acta Oncol 2013 May;52(4):736-44. Epub 2013 feb 26
PMID: 23438358
Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor.
Hum Reprod 2013 Jul;28(7):1995-2002. Epub 2013 mai 2
PMID: 23639623
Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in SPRY4.
Hum Mol Genet 2013 Aug;22(16):3373-80. Epub 2013 mai 2
PMID: 23640991
Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort.
Radiother Oncol 2013 Jul;108(1):55-60. Epub 2013 jul 25
PMID: 23891095
Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys 2012 Jan;82(1):442-7. Epub 2010 okt 14
PMID: 20950963
The prognostic impact of tumor cell expression of estrogen receptor-a, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer.
Cancer 2012 Jan;118(1):157-63. Epub 2011 jun 28
PMID: 21713768
Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update.
Int J Hyperthermia 2012;28(6):549-53. Epub 2012 jul 13
PMID: 22788973
Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population.
Hum Reprod 2012 May;27(5):1525-35. Epub 2012 mar 8
PMID: 22402210
High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Acta Oncol 2012 Feb;51(2):168-76. Epub 2011 des 19
PMID: 22175254
Testicular germ cell tumours - still many challenges.
Acta Oncol 2012 Feb;51(2):147-50.
PMID: 22263970
Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer.
Br J Cancer 2012 Nov;107(11):1833-9.
PMID: 23169336
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
Int J Radiat Oncol Biol Phys 2012 Jun;83(2):e173-80. Epub 2012 mar 19
PMID: 22436791
Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients.
Br J Cancer 2012 Feb;106(4):756-62.
PMID: 22333708
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.
Br J Cancer 2012 Nov;107(10):1684-91. Epub 2012 okt 25
PMID: 23099809
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
J Clin Oncol 2012 May;30(15):1755-62. Epub 2012 apr 2
PMID: 22473155
Medikamentell Kreftbehandling. Cytostatikaboken, 1-661
Univ. i Oslo, Med Fak, Inst for Klinisk Medisin, Avd. for farmakologi, 8. utgave 2016
Kreftbiologi og Medikamentell terapi. Kap. 1, 13-46
Medikamentell Kreftbehandling. Cytostatikaboken 2016
Medikamentell kreftbehandling. Kap. 2 ,47-56
Medikamentell kreftbehandling. Cytostatikaboken 2016
Bivirkninger. Kap. 4, 67-97
Medikamentell kreftbehandling. Cytostatikaboken. 2016
Metabolske forstyrrelser ved kreft. Kap 7,141-152
Medikamentell kreftbehandling. Cytostaticaboken. 2016
Gastrointestinal kreft. Kap. 28, 481-499
Medikamentell kreftbehandling. Cytostatikaboken, 2016
Kreft i nyre, urinveier og prostata. Kap. 31, 528-541
Medikamentell kreftbehandling. Cytostatikaboken, 2016
Cancer testis. Kap. 32, 542-551.
medikamentell kreftbehandling. Cytostaticaboken, 2016
Molecular and clinicopathological factors in colorectal cancer with emphasis on prognostic and predictive factors for survival
- Disputert:
- november 2016
- Hovedveileder:
- Olav Dahl
PhD
- Disputert:
- desember 2012
- Hovedveileder:
- Olav Dahl
- Kristian Eg Storli Prosjektdeltaker
- Jon Espen Dale Ph.d.-kandidat
- Nina Benedikte Rosenlund Prosjektdeltaker
- Luka Stanisavljevic Prosjektdeltaker
- Kjersti Elvestad Hestetun Ph.d.-kandidat
- Havjin Jacob Ph.d.-kandidat
- Mette Pernille Myklebust Medveileder
- Olav Dahl Prosjektleder
- Yvonne Müller Prosjektdeltaker
- Marianne Brydøy Postdoktor
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest